Table 3 Correlations between clinicopathological features and Transgelin expression in all the included cases
Characteristics | All (N = 44) | Transgelin | Â | Â | Â |
|---|---|---|---|---|---|
| Â | Â | Negative (N = 25) | Focal weak +ve (N = 6) | Diffuse strong +ve (N = 13) | p-value |
| Â | No. (%) | No. (%) | No. (%) | No. (%) | Â |
Age (years) | |||||
 Mean ± SD | 56.84 ±7.93 | 52.84 ±7.56 | 65 ±4.97 | 60.76 ±4.16 | <0.001* |
 Median (Range) | 57 (39-72) | 51 (39-72) | 63.50 (59-72) | 60 (56-70) |  |
 ≤ 55 years | 18 (40.9%) | 18 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
 > 55 years | 26 (59.1%) | 7 (26.9%) | 6 (23.1%) | 13 (50%) |  |
Histopathology | |||||
 LMS | 22 (50%) | 3 (13.6%) | 6 (27.3%) | 13 (59.1%) | <0.001‡ |
 ESS | 22 (50%) | 22 (100%) | 0 (0%) | 0 (0%) |  |
Grade | |||||
 Grade I | 9 (20.5%) | 7 (77.8%) | 2 (22.2%) | 0 (0%) | 0.014‡ |
 Grade II | 12 (27.3%) | 5 (41.7%) | 4 (33.3%) | 3 (25%) |  |
 Grade III | 23 (52.3%) | 13 (56.5%) | 0 (0%) | 10 (43.5%) |  |
Extrauterine extension | |||||
 Absent | 6 (13.6%) | 5 (83.3%) | 1 (16.7%) | 0 (0%) | <0.001‡ |
 Present | 9 (20.5%) | 4 (44.4%) | 5 (55.6%) | 0 (0%) |  |
 N/A | 29 (65.9%) | 16 (55.2%) | 0 (0%) | 13 (44.8%) |  |
LVSI | |||||
 Absent | 21 (47.7%) | 10 (47.6%) | 6 (28.6%) | 5 (23.8%) | 0.022‡ |
 Present | 23 (52.3%) | 15 (65.2%) | 0 (0%) | 8 (34.8%) |  |
Adnexal invasion | |||||
 Absent | 11 (25%) | 7 (63.6%) | 4 (36.4%) | 0 (0%) | 0.007‡ |
 Present | 33 (75%) | 18 (54.5%) | 2 (6.1%) | 13 (39.4%) |  |
Lymph node | |||||
 Negative | 16 (36.4%) | 9 (56.2%) | 6 (37.5%) | 1 (6.2%) | 0.001‡ |
 Positive | 28 (63.6%) | 16 (57.1%) | 0 (0%) | 12 (42.9%) |  |
FIGO Stage | |||||
 Stage I | 6 (13.6%) | 5 (83.3%) | 1 (16.7%) | 0 (0%) | 0.001‡ |
 Stage II | 10 (22.7%) | 4 (40%) | 5 (50%) | 1 (10%) |  |
 Stage III | 13 (29.5%) | 5 (38.5%) | 0 (0%) | 8 (61.5%) |  |
 Stage IV | 15 (34.1%) | 11 (73.3%) | 0 (0%) | 4 (26.7%) |  |
Stathmin | |||||
 Negative | 19 (43.2%) | 19 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
 Focal weak +ve | 12 (27.3%) | 5 (41.7%) | 6 (50%) | 1 (8.3%) |  |
 Diffuse strong +ve | 13 (29.5%) | 1 (7.7%) | 0 (0%) | 12 (92.3%) |  |
BCOR | |||||
 Negative | 23 (52.3%) | 7 (30.4%) | 6 (26.1%) | 10 (43.5%) | 0.004‡ |
 Focal weak +ve | 7 (15.9%) | 5 (71.4%) | 0 (0%) | 2 (28.6%) |  |
 Diffuse strong +ve | 14 (31.8%) | 13 (92.9%) | 0 (0%) | 1 (7.1%) |  |
Cyclin-D1 | |||||
 Negative | 24 (54.5%) | 5 (20.8%) | 6 (25%) | 13 (54.2%) | <0.001‡ |
 Focal weak +ve | 5 (11.4%) | 5 (100%) | 0 (0%) | 0 (0%) |  |
 Diffuse strong +ve | 15 (34.1%) | 15 (100%) | 0 (0%) | 0 (0%) |  |